Oncology & Cancer

A new molecular target to improve neuroblastoma treatment

The annual mortality rate in childhood cancer of the sympathetic nervous system, or neuroblastoma, is 10 per million between the ages of zero and four. A collaborative work between Basque and Valencian researchers has identified ...

Oncology & Cancer

Nuclear protein causes neuroblastoma to become more aggressive

Aggressive forms of neuroblastoma contain a specific protein in their cells' nuclei that is not found in the nuclei of more benign forms of the cancer, and the discovery, made through research from the University of Rochester ...

Oncology & Cancer

Loss of a microRNA family, let-7, found key in neuroblastoma

Great strides have been made in treating neuroblastoma, the most common cancer in infants and toddlers. However, advanced cases are often fatal, and children who survive often face life-long physical and intellectual challenges ...

Oncology & Cancer

Doctors unleash new weapon to fight pediatric neuroblastoma

For seven months, three-year-old Emil Abbasov underwent chemotherapy to fight the tangerine-sized, cancerous tumor growing in his abdomen. But each time, the tumor resisted harder. Each time, he felt more side effects.

Oncology & Cancer

Cancer-driving signals cause high-risk neuroblastoma

Researchers have discovered details of the abnormal molecular signals and biological events that drive a high-risk form of the childhood cancer neuroblastoma. They aim to use these findings to develop more effective targeted ...

Oncology & Cancer

New drug for neuroblastoma shows promise in phase I study

Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric ...

page 11 from 14